Unknown

Dataset Information

0

Comparison of Likert and PI-RADS version 2 MRI scoring systems for the detection of clinically significant prostate cancer.


ABSTRACT:

Objective

To compare the performance of Likert and Prostate Imaging-Reporting and Data System (PI-RADS) multiparametric (mp) MRI scoring systems for detecting clinically significant prostate cancer (csPCa).

Methods

199 biopsy-naïve males undergoing prostate mpMRI were prospectively scored with Likert and PI-RADS systems by four experienced radiologists. A binary cut-off (threshold score ≥3) was used to analyze histological results by three groups: negative, insignificant disease (Gleason 3 + 3; iPCa), and csPCa (Gleason ≥3 +4). Lesion-level results and prostate zonal location were also compared.

Results

129/199 (64.8%) males underwent biopsy, 96 with Likert or PI-RADS score ≥3, and 21 with negative MRI. A further 12 patients were biopsied during follow-up (mean 507 days). Prostate cancer was diagnosed in 87/199 (43.7%) patients, 65 with (33.6%) csPCa. 30/92 (32.6%) patients with negative MRI were biopsied, with an NPV of 83.3% for cancer and 86.7% for csPCa. Likert and PI-RADS score differences were observed in 92 patients (46.2%), but only for 16 patients (8%) at threshold score ≥3. Likert scoring had higher specificity than PI-RADS (0.77 vs 0.66), higher area under the curve (0.92 vs 0.87, p = 0.002) and higher PPV (0.66 vs 0.58); NPV and sensitivity were the same. Likert had more five score results (58%) compared to PI-RADS (36%), but with similar csCPa detection (81.0 and 80.6% respectively). Likert demonstrated lower proportion of false positive in the predominately AFMS-involving lesions.

Conclusion

Likert and PI-RADS systems both demonstrate high cancer detection rates. Likert scoring had a higher AUC with moderately higher specificity and lower positive call rate and could potentially help to reduce the number of unnecessary biopsies performed.

Advances in knowledge

This paper illustrates that the Likert scoring system has potential to help urologists reduce the number of prostate biopsies performed.

SUBMITTER: Zawaideh JP 

PROVIDER: S-EPMC7446003 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7245434 | biostudies-literature
| S-EPMC5033350 | biostudies-literature
| S-EPMC6935323 | biostudies-literature
| S-EPMC7188610 | biostudies-literature
| S-EPMC8459209 | biostudies-literature
| S-EPMC6677282 | biostudies-other
| S-EPMC8261422 | biostudies-literature
| S-EPMC8392157 | biostudies-literature